+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dyslipidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 330 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589950
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Drugs In Development, 2022, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 34, 21, 27, 3, 38, 16 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageDyslipidemia - Overview
Dyslipidemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Dyslipidemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Dyslipidemia - Companies Involved in Therapeutics DevelopmentDyslipidemia - Drug ProfilesDyslipidemia - Dormant ProjectsDyslipidemia - Discontinued ProductsDyslipidemia - Product Development Milestones
Featured News & Press Releases
  • Feb 25, 2022: Arrowhead concludes enrolment in Phase IIb mixed dyslipidemia trial
  • Dec 22, 2021: Akeso: Early completion of patient enrollment of Ebronucimab (PCSK9 monoclonal antibody, AK102) in a phase III clinical trial for primary hypercholesterolemia and mixed hyperlipidemia in China
  • Nov 15, 2021: Arrowhead presents new clinical data on ARO-APOC3 at AHA 2021
  • Nov 15, 2021: NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial
  • Nov 03, 2021: Ionis begins clinical trial of severe hypertriglyceridemia medicine
  • Nov 02, 2021: Rivus reports positive data from trial of cardiometabolic disease therapy
  • Sep 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of ARO-APOC3 for treatment of mixed dyslipidemia
  • Jul 28, 2021: NewAmsterdam Pharma reports positive results from phase 2 study of Oral Obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins
  • Jul 06, 2021: Novartis announces complete response resubmission for inclisiran new drug application
  • Jun 30, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-ANG3 for treatment of mixed dyslipidemia
  • Jun 03, 2021: Arrowhead Pharmaceuticals initiates phase 2b study of investigational ARO-APOC3 for treatment of severe hypertriglyceridemia
  • May 16, 2021: tctMD: Evinacumab lowers triglycerides in severe hypertriglyceridemia
  • Mar 22, 2021: JW Pharmaceutical: Proving the effect of improving lipids as a result of phase 3 clinical trial of RivaroJet 'NDA application'
  • Mar 01, 2021: Arrowhead Pharmaceuticals files IND to begin phase 2b study of ARO-APOC3 in patients with severe hypertriglyceridemia
  • Feb 01, 2021: Matinas BioPharma announces topline results from ENHANCE-IT study of LYPDISO against Vascepa
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Dyslipidemia, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Dyslipidemia - Pipeline by 89bio Inc, 2022
  • Dyslipidemia - Pipeline by ABIONYX Pharma SA, 2022
  • Dyslipidemia - Pipeline by Addpharma Inc, 2022
  • Dyslipidemia - Pipeline by Afimmune Biopharma Ltd, 2022
  • Dyslipidemia - Pipeline by Akcea Therapeutics Inc, 2022
  • Dyslipidemia - Pipeline by Akeso Inc, 2022
  • Dyslipidemia - Pipeline by Amarin Corp Plc, 2022
  • Dyslipidemia - Pipeline by Arrakis Therapeutics Inc, 2022
  • Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, 2022
  • Dyslipidemia - Pipeline by AstraZeneca Plc, 2022
  • Dyslipidemia - Pipeline by AVVA Pharmaceuticals AG, 2022
  • Dyslipidemia - Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
  • Dyslipidemia - Pipeline by Bio-Thera Solutions Ltd, 2022
  • Dyslipidemia - Pipeline by BioRestorative Therapies Inc, 2022
  • Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Cardax Inc, 2022
  • Dyslipidemia - Pipeline by Celltrion Inc, 2022
  • Dyslipidemia - Pipeline by Centaurus Therapeutics Inc, 2022
  • Dyslipidemia - Pipeline by Centeer BioTherapeutics Ltd Co, 2022
  • Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
  • Dyslipidemia - Pipeline by CMG Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Corvidia Therapeutics Inc, 2022
  • Dyslipidemia - Pipeline by CVI Pharmaceuticals US Inc, 2022
  • Dyslipidemia - Pipeline by Daewon Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Daiichi Sankyo Co Ltd, 2022
  • Dyslipidemia - Pipeline by Delivra Corp, 2022
  • Dyslipidemia - Pipeline by Dicerna Pharmaceuticals Inc, 2022
  • Dyslipidemia - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
  • Dyslipidemia - Pipeline by Eccogene (Shanghai) Co Ltd, 2022
  • Dyslipidemia - Pipeline by Eli Lilly and Co, 2022
  • Dyslipidemia - Pipeline by Esperion Therapeutics Inc, 2022
  • Dyslipidemia - Pipeline by Genu Pharma Co Ltd, 2022
  • Dyslipidemia - Pipeline by Gilead Sciences Inc, 2022
  • Dyslipidemia - Pipeline by Golden Biotechnology Corp, 2022
  • Dyslipidemia - Pipeline by Guangzhou Jiayue Pharmaceutical Technology Co Ltd, 2022
  • Dyslipidemia - Pipeline by Halo Therapeutics Ltd, 2022
  • Dyslipidemia - Pipeline by Handok Inc, 2022
  • Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
  • Dyslipidemia - Pipeline by HK inno.N Corp, 2022
  • Dyslipidemia - Pipeline by Huons Co Ltd, 2022
  • Dyslipidemia - Pipeline by Ildong Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Inovio Pharmaceuticals Inc, 2022
  • Dyslipidemia - Pipeline by Inversago Pharma Inc, 2022
  • Dyslipidemia - Pipeline by Japan Tobacco Inc, 2022
  • Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Jenrin Discovery Inc, 2022
  • Dyslipidemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
  • Dyslipidemia - Pipeline by JW Pharmaceutical Corp, 2022
  • Dyslipidemia - Pipeline by Korea United Pharm Inc, 2022
  • Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Kowa Co Ltd, 2022
  • Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Kyttaro Ltd, 2022
  • Dyslipidemia - Pipeline by Kyung Dong Co Ltd, 2022
  • Dyslipidemia - Pipeline by Les Laboratoires Servier SAS, 2022
  • Dyslipidemia - Pipeline by Liid Pharmaceuticals Inc, 2022
  • Dyslipidemia - Pipeline by LipimetiX Development Inc, 2022
  • Dyslipidemia - Pipeline by Lyndra Therapeutics Inc., 2022
  • Dyslipidemia - Pipeline by Madrigal Pharmaceuticals Inc, 2022
  • Dyslipidemia - Pipeline by Matinas BioPharma Holdings Inc, 2022
  • Dyslipidemia - Pipeline by MD Healthcare Inc, 2022
  • Dyslipidemia - Pipeline by Mochida Pharmaceutical Co Ltd, 2022
  • Dyslipidemia - Pipeline by Navipharm Co Ltd, 2022
  • Dyslipidemia - Pipeline by NewAmsterdam Pharma BV, 2022
  • Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, 2022
  • Dyslipidemia - Pipeline by Nissan Chemical Corp, 2022
  • Dyslipidemia - Pipeline by NorthSea Therapeutics BV, 2022
  • Dyslipidemia - Pipeline by NovalGen Ltd, 2022
  • Dyslipidemia - Pipeline by Novartis AG, 2022
  • Dyslipidemia - Pipeline by Nubiyota LLC, 2022
  • Dyslipidemia - Pipeline by NuSirt Biopharma Inc, 2022
  • Dyslipidemia - Pipeline by Omeros Corp, 2022
  • Dyslipidemia - Pipeline by Orient Pharma Co Ltd, 2022
  • Dyslipidemia - Pipeline by Pharmena SA, 2022
  • Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, 2022
  • Dyslipidemia - Pipeline by Rivus Pharmaceuticals Inc, 2022
  • Dyslipidemia - Pipeline by Saliogen Therapeutics Inc, 2022
  • Dyslipidemia - Pipeline by Sequor Pharmaceuticals LLC, 2022
  • Dyslipidemia - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
  • Dyslipidemia - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
  • Dyslipidemia - Pipeline by Sirnaomics Ltd, 2022
  • Dyslipidemia - Pipeline by SJT Molecular Research SL, 2022
  • Dyslipidemia - Pipeline by Staten Biotechnology BV, 2022
  • Dyslipidemia - Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
  • Dyslipidemia - Pipeline by Sveikatal Inc, 2022
  • Dyslipidemia - Pipeline by Synokem Pharmaceuticals Ltd, 2022
  • Dyslipidemia - Pipeline by Tetranov International Inc, 2022
  • Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, 2022
  • Dyslipidemia - Pipeline by Viking Therapeutics Inc, 2022
  • Dyslipidemia - Pipeline by Yooyoung Pharm Co Ltd, 2022
  • Dyslipidemia - Pipeline by Yungjin Pharm Co Ltd, 2022
  • Dyslipidemia - Pipeline by Zydus Lifesciences Ltd, 2022
  • Dyslipidemia - Dormant Projects, 2022
  • Dyslipidemia - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Dyslipidemia, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 89bio Inc
  • ABIONYX Pharma SA
  • Addpharma Inc
  • Afimmune Biopharma Ltd
  • Akcea Therapeutics Inc
  • Akeso Inc
  • Amarin Corp Plc
  • Arrakis Therapeutics Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • AVVA Pharmaceuticals AG
  • Beijing Mabworks Biotech Co Ltd
  • Bio-Thera Solutions Ltd
  • BioRestorative Therapies Inc
  • Boryung Pharmaceutical Co Ltd
  • Cardax Inc
  • Celltrion Inc
  • Centaurus Therapeutics Inc
  • Centeer BioTherapeutics Ltd Co
  • Chong Kun Dang Pharmaceutical Corp
  • CMG Pharmaceutical Co Ltd
  • Corvidia Therapeutics Inc
  • CVI Pharmaceuticals US Inc
  • Daewon Pharmaceutical Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Delivra Corp
  • Dicerna Pharmaceuticals Inc
  • DongKoo Bio & Pharma Co Ltd
  • Eccogene (Shanghai) Co Ltd
  • Eli Lilly and Co
  • Esperion Therapeutics Inc
  • Genu Pharma Co Ltd
  • Gilead Sciences Inc
  • Golden Biotechnology Corp
  • Guangzhou Jiayue Pharmaceutical Technology Co Ltd
  • Halo Therapeutics Ltd
  • Handok Inc
  • Hanmi Pharmaceuticals Co Ltd
  • HK inno.N Corp
  • Huons Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Inovio Pharmaceuticals Inc
  • Inversago Pharma Inc
  • Japan Tobacco Inc
  • Jeil Pharmaceutical Co Ltd
  • Jenrin Discovery Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • JW Pharmaceutical Corp
  • Korea United Pharm Inc
  • Kotobuki Pharmaceutical Co Ltd
  • Kowa Co Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Kyttaro Ltd
  • Kyung Dong Co Ltd
  • Les Laboratoires Servier SAS
  • Liid Pharmaceuticals Inc
  • LipimetiX Development Inc
  • Lyndra Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc
  • Matinas BioPharma Holdings Inc
  • MD Healthcare Inc
  • Mochida Pharmaceutical Co Ltd
  • Navipharm Co Ltd
  • NewAmsterdam Pharma BV
  • Nippon Chemiphar Co Ltd
  • Nissan Chemical Corp
  • NorthSea Therapeutics BV
  • NovalGen Ltd
  • Novartis AG
  • Nubiyota LLC
  • NuSirt Biopharma Inc
  • Omeros Corp
  • Orient Pharma Co Ltd
  • Pharmena SA
  • Regeneron Pharmaceuticals Inc
  • Rivus Pharmaceuticals Inc
  • Saliogen Therapeutics Inc
  • Sequor Pharmaceuticals LLC
  • Shanghai Junshi Bioscience Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Sirnaomics Ltd
  • SJT Molecular Research SL
  • Staten Biotechnology BV
  • Suzhou Ribo Life Sciences Co Ltd
  • Sveikatal Inc
  • Synokem Pharmaceuticals Ltd
  • Tetranov International Inc
  • Torrent Pharmaceuticals Ltd
  • Viking Therapeutics Inc
  • Yooyoung Pharm Co Ltd
  • Yungjin Pharm Co Ltd
  • Zydus Lifesciences Ltd